The current research point of view is that malignant changes such as anemia, electrolyte imbalance, and abnormal lipid metabolism in patients with end-stage renal disease are closely related to the decline of erythropoietin (EPO) and glomerular filtration capacity [2]. This evidence concerns the gene EPO and anemia.